Skip to main content
The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study.
- Author(s): McDonald, Craig M;
- Henricson, Erik K;
- Abresch, R Ted;
- Florence, Julaine M;
- Eagle, Michelle;
- Gappmaier, Eduard;
- Glanzman, Allan M;
- PTC124-GD-007-DMD Study Group;
- Spiegel, Robert;
- Barth, Jay;
- Elfring, Gary;
- Reha, Allen;
- Peltz, Stuart
- et al.
Published Web Locationhttps://doi.org/10.1002/mus.23902
IntroductionDuchenne muscular dystrophy (DMD) subjects ≥5 years with nonsense mutations were followed for 48 weeks in a multicenter, randomized, double-blind, placebo-controlled trial of ataluren. Placebo arm data (N = 57) provided insight into the natural history of the 6-minute walk test (6MWT) and other endpoints.
MethodsEvaluations performed every 6 weeks included the 6-minute walk distance (6MWD), timed function tests (TFTs), and quantitative strength using hand-held myometry.
ResultsBaseline age (≥7 years), 6MWD, and selected TFT performance are strong predictors of decline in ambulation (Δ6MWD) and time to 10% worsening in 6MWD. A baseline 6MWD of <350 meters was associated with greater functional decline, and loss of ambulation was only seen in those with baseline 6MWD <325 meters. Only 1 of 42 (2.3%) subjects able to stand from supine lost ambulation.
ConclusionFindings confirm the clinical meaningfulness of the 6MWD as the most accepted primary clinical endpoint in ambulatory DMD trials.
For improved accessibility of PDF content, download the file to your device.